REVILDA 500/1000 mg Tablets

Description

Type 2 diabetes mellitus (T2DM) is a dual disease, characterized by islet (beta- and alpha-) cell dysfunction in the setting of insulin resistance.

Data suggests that when a gliptin is added to patients inadequately controlled with metformin there results in a substantial improvement in Glycated Haemoglobin (HbA1c) (range 0.50 – 0.75%) with as many twice as several patients achieving an HbA1c of <7% compared to metformin alone.

Vildagliptin

• Drug class: Oral antidiabetic agents – Dipeptidyl peptidase IV (DPP-IV) inhibitors
• Inhibits dipeptidyl peptidase-4 and prevents degradation of glucagon-like peptide-1 in patients with type-2 diabetes mellitus.
• Rapidly & well-absorbed with an absolute bioavailability of 85%.
• Recent evidence from T2DM patients with mild hyperglycemia indicates that vildagliptin attenuates deterioration of β-cell function over long-term treatment

Metformin

• Drug class: Biguanides
• Metformin acts primarily in the liver by reducing glucose output and, secondarily, by augmenting glucose uptake in the peripheral tissues, chiefly muscle.

Combination

• From a pathogenic perspective, combining an agent primarily targeting insulin resistance, like metformin, with an agent primarily targeting the β-cell, like vildagliptin, is a logical approach.